SHANGHAI, Oct. 30, 2026 /PRNewswire/ — Nuance Pharma announced that the first patient has been dosed in the REACH Phase III clinical trial evaluating STG320 (Actair®) for the treatment of house dust mite-induced allergic rhinitis in China.
Stallergenes Greer’s Actair® is a sublingual tablet currently marketed in 21 countries and territories under brand names including Actair®, Orylmyte® and Aitmyte®. Further market expansion is underway.
Actair Study in China
On May 22nd, 2026, Nuance Pharma announced that the National Medical Products Administration (NMPA) has cleared its Investigational New Drug (IND) application, designed to initiate a pivotal clinical trial of Actair® for the treatment of house dust mite-induced allergic rhinitis in China.
In October 2026, Nuance Pharma announces the first patient dosed in the REACH Phase III trial, a randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Actair® over a 12-month treatment period in patients with allergic rhinitis, with or without concomitant asthma.
“We are excited to announce the first patient dosing in the REACH Phase III trial. Together with the progress made through our early access programs, this achievement moves us one step closer to delivering a new allergy treatment to Chinese patients,” said Mark Lotter, Founder and Chief Executive Officer of Nuance Pharma. “Actair® offers an innovative approach to treating house dust mite allergy, and we look forward to introducing this innovation in China as soon as possible,” said Dr. Charlie Chen, Chief Operating Officer of Nuance Pharma.
“We are pleased our development partner, Nuance Pharma, has begun pivotal studies with Actair® in mainland China,” said Anette Weber, Chief Executive Officer a.i. of Stallergenes Greer. “This is a significant achievement and, given Actair®’s established commercial track record across 21 countries, we are excited about its potential to address the growing demand for innovative allergy treatments among Chinese patients.”
The first patient dosing follows a series of recent milestones reinforcing Nuance Pharma’s commitment to the Chinese allergy market. In September 2025, the company entered into an exclusive long-term partnership with Stallergenes Greer for the development and registration of Actair® in China, with Nuance Pharma retaining responsibility for subsequent commercialization. In January 2026, Actair® received approval from the Pharmaceutical Administration Bureau of Macau. In May 2026, Nuance Pharma launched Actair® in China’s Hainan Boao Pilot Zone through an early access program. Most recently, in May 2026, the National Medical Products Administration (NMPA) has cleared Actair® Investigational New Drug (IND) application.
About Nuance Pharma
Nuance Pharma is an innovation-driven biopharmaceutical company with a late-stage clinical pipeline and a portfolio of commercial-stage assets. Focused on specialty care, Nuance has established a differentiated combination of commercialized products and an innovative pipeline spanning respiratory disease. With a mission to address critical unmet medical needs across the Asia-Pacific region, Nuance Pharma deploys its proprietary Dual Wheel model — simultaneously advancing a globally competitive pipeline while maintaining a self-sustaining commercial operation in China and across Asia.
For more information, please visit www.nuancepharma.com
About Stallergenes Greer International AG
Headquartered in Baar, Switzerland, Stallergenes Greer is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. Backed by more than 120 years of expertise and innovation, its products are available to patients in 46 countries.
For more information, please visit www.stallergenesgreer.com
Forward-looking Statements: This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
Statement on the Use of Artificial Intelligence Tools and Illustrative Images: Certain text, images, and design elements in this press release were generated or edited with the assistance of artificial intelligence tools and published following human review. The illustrative images and visual elements are used solely to help explain the content of this press release. They are not intended to depict or recreate any specific individual, event, clinical setting, or actual product, nor do they constitute any description, recommendation, promise, or guarantee regarding any treatment method, clinical outcome, dosage or administration, product design, or appearance. For information on the indications, dosage and administration, safety, design, and appearance of any specific product, the approved product labeling and materials officially issued by the Company shall prevail. The factual information, data, and quotations in this press release are not based on the relevant illustrative images or visual elements.
